Chi Zhang1,2,3, Jia Wang1, Ya Yang4, Er-Li Ma5, Hou-Wen Lin1,2, Bing-Long Liu5, Zhi-Chun Gu1,3. 1. Department of Pharmacy, 71140Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. School of Medicine, Tongji University, Shanghai, China. 3. Drug Clinical Comprehensive Evaluation Group, Shanghai Pharmaceutical Association, Shanghai, China. 4. Department of Medical Administration, 71140Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 5. Shanghai Pharmaceutical Association, Shanghai, China.
Abstract
AIM: Non-vitamin K antagonist oral anticoagulants (NOACs) were developed as an alternative to warfarin to prevent thromboembolism in patients with atrial fibrillation (AF), prosthetic heart valves, venous thromboembolism (VTE), or other thrombotic disorders. The aim of this study is to explore the trends in prescribing OACs, including warfarin and NOACs, in Shanghai, China. METHODS: Prescription data of OACs were retrospectively collected from Rx Analysis System from 2010 to 2020 in Shanghai, China. Comparisons were made on the trends of each OACs according to different indications, age groups, and hospital grades. The costs and the contribution of individual OACs were also explored. RESULTS: Growing trends in overall prescriptions for OACs were observed. The prescriptions of NOACs were significantly increased since 2016, while the prescriptions of warfarin kept decreasing since 2017. A highly statistically significant increase in prescriptions of Rivaroxaban was observed from 2016 to 2020 (P < .001). Despite the price reduction of rivaroxaban in 2018, the total cost of rivaroxaban continued to rise (P < .001). Rivaroxaban emerged as a preferred NOAC in both indications of AF and VTE, and accounted for more than three-quarters of the total costs for OACs since 2019. Compared with rivaroxaban, the prescription numbers of dabigatran and apixaban were much smaller, and the growth of prescriptions were much slower. Differences in prescribing patterns in different indications, age groups, and grades of hospitals were also founded. CONCLUSION: There has been a rapid increase in the use of OAC over the last 11 years in Shanghai, China. NOACs have been adopted rapidly, and have been gradually replacing warfarin. Warfarin remains the top choice for certain patients with valvular heart disease. Future studies are warranted considering changes in the OAC use in a larger scale, as well as the rationality and its influence factors on OAC use.
AIM: Non-vitamin K antagonist oral anticoagulants (NOACs) were developed as an alternative to warfarin to prevent thromboembolism in patients with atrial fibrillation (AF), prosthetic heart valves, venous thromboembolism (VTE), or other thrombotic disorders. The aim of this study is to explore the trends in prescribing OACs, including warfarin and NOACs, in Shanghai, China. METHODS: Prescription data of OACs were retrospectively collected from Rx Analysis System from 2010 to 2020 in Shanghai, China. Comparisons were made on the trends of each OACs according to different indications, age groups, and hospital grades. The costs and the contribution of individual OACs were also explored. RESULTS: Growing trends in overall prescriptions for OACs were observed. The prescriptions of NOACs were significantly increased since 2016, while the prescriptions of warfarin kept decreasing since 2017. A highly statistically significant increase in prescriptions of Rivaroxaban was observed from 2016 to 2020 (P < .001). Despite the price reduction of rivaroxaban in 2018, the total cost of rivaroxaban continued to rise (P < .001). Rivaroxaban emerged as a preferred NOAC in both indications of AF and VTE, and accounted for more than three-quarters of the total costs for OACs since 2019. Compared with rivaroxaban, the prescription numbers of dabigatran and apixaban were much smaller, and the growth of prescriptions were much slower. Differences in prescribing patterns in different indications, age groups, and grades of hospitals were also founded. CONCLUSION: There has been a rapid increase in the use of OAC over the last 11 years in Shanghai, China. NOACs have been adopted rapidly, and have been gradually replacing warfarin. Warfarin remains the top choice for certain patients with valvular heart disease. Future studies are warranted considering changes in the OAC use in a larger scale, as well as the rationality and its influence factors on OAC use.
Authors: Jan Steffel; Ronan Collins; Matthias Antz; Pieter Cornu; Lien Desteghe; Karl Georg Haeusler; Jonas Oldgren; Holger Reinecke; Vanessa Roldan-Schilling; Nigel Rowell; Peter Sinnaeve; Thomas Vanassche; Tatjana Potpara; A John Camm; Hein Heidbüchel; Gregory Y H Lip; Thomas Deneke; Nikolaos Dagres; Giuseppe Boriani; Tze-Fan Chao; Eue-Keun Choi; Mellanie True Hills; Itamar de Souza Santos; Deirdre A Lane; Dan Atar; Boyoung Joung; Oana Maria Cole; Mark Field Journal: Europace Date: 2021-04-25 Impact factor: 5.214
Authors: Connie W Tsao; Aaron W Aday; Zaid I Almarzooq; Alvaro Alonso; Andrea Z Beaton; Marcio S Bittencourt; Amelia K Boehme; Alfred E Buxton; April P Carson; Yvonne Commodore-Mensah; Mitchell S V Elkind; Kelly R Evenson; Chete Eze-Nliam; Jane F Ferguson; Giuliano Generoso; Jennifer E Ho; Rizwan Kalani; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Deborah A Levine; Tené T Lewis; Junxiu Liu; Matthew Shane Loop; Jun Ma; Michael E Mussolino; Sankar D Navaneethan; Amanda Marma Perak; Remy Poudel; Mary Rezk-Hanna; Gregory A Roth; Emily B Schroeder; Svati H Shah; Evan L Thacker; Lisa B VanWagner; Salim S Virani; Jenifer H Voecks; Nae-Yuh Wang; Kristine Yaffe; Seth S Martin Journal: Circulation Date: 2022-01-26 Impact factor: 39.918
Authors: Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins Journal: Eur Heart J Date: 2021-02-01 Impact factor: 29.983